Could Weight-Loss Medications Eliminate the Need for Knee Replacement Surgery?

Weight-Loss Drugs Show Promise in Reducing Knee Replacement Surgeries

Groundbreaking new research indicates that popular weight-loss medications could spare tens of thousands of patients from knee replacement surgery each year. The findings offer fresh hope for millions of people worldwide living with debilitating knee arthritis.

The Scale of the Knee Arthritis Problem

Osteoarthritis is a global health crisis, affecting more than 500 million people worldwide. Knee arthritis is the most prevalent form of the condition, with approximately 14 million Americans and over 5 million people in the UK currently diagnosed. Each year, more than 120,000 knee replacement procedures are performed in the UK alone, placing enormous pressure on healthcare systems.

Carrying excess weight plays a major role in the development of knee arthritis, as additional body mass places increased mechanical stress on joint tissue, accelerating wear and deterioration.

What the Research Found

Scientists at the University of Maryland School of Medicine conducted a large-scale analysis of health data covering 6.8 million adults diagnosed with knee osteoarthritis between 2010 and 2024. Researchers identified a matched sample of 42,000 individuals who had been taking GLP-1 receptor agonist medications — a class that includes well-known drugs such as Ozempic, Wegovy, and Mounjaro — for at least one year. This group was compared against an equal number of similar patients who had not taken these medications. A separate analysis was also conducted on nearly 31,000 patients who had used GLP-1 drugs for a minimum of three years.

Participants were monitored at regular intervals over an eight-year period to evaluate their likelihood of requiring knee replacement surgery.

Key Findings: Longer Use Delivers Greater Benefits

The study, published in the journal Regional Anesthesia & Pain Medicine, revealed that even one year of GLP-1 medication use was associated with meaningful reductions in surgical risk. Specifically:

• One year of use was linked to a 1.4-percentage-point lower risk of knee replacement at the three-year follow-up, rising to a 2.8-percentage-point reduction after eight years.
• Three years of use of newer agents such as semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro) was associated with nearly a 5-percentage-point reduction in the likelihood of needing knee surgery after eight years.

The researchers projected that if all eligible patients with knee arthritis and obesity or metabolic disease were treated with semaglutide or tirzepatide for three or more years, the US could see up to 14,400 fewer knee replacements annually, while the UK could avoid more than 1,500 procedures per year.

Why These Drugs May Help Beyond Weight Loss

While weight reduction itself reduces joint load, researchers believe these medications may offer additional benefits. The study authors noted that GLP-1 receptor agonists may act through complementary anti-inflammatory and pain-relieving mechanisms that go beyond simply helping patients lose weight.

Mark Bowditch, a consultant knee surgeon and former president of the British Orthopaedic Association, acknowledged there may be "direct anti-inflammatory and possibly cartilage-protective effects of GLP-1 receptor agonists that operate through weight-independent mechanisms." However, he was careful to emphasize that the study does not definitively prove these drugs prevent surgery, and cautioned that GLP-1 medications are not currently approved for treating osteoarthritis.

"We would strongly caution against their use for this purpose outside of clinical trials," Bowditch stated.

Expert Perspectives on the Broader Implications

Professor Lucy Donaldson, Director of Research at Arthritis UK, welcomed the findings, suggesting they could deepen our understanding of how weight-management medications might help certain patients delay or altogether avoid joint replacement surgery.

"Maintaining a healthy weight can play a vital role in managing osteoarthritis, particularly in weight-bearing joints such as the knees and hips," she said. "Even modest weight loss can improve symptoms and, in some cases, slow the progression of the condition."

What This Means for Patients

While these findings are promising, medical experts agree that more research is needed before GLP-1 drugs are recommended specifically for osteoarthritis management. Patients currently managing knee arthritis should consult their healthcare provider before making any changes to their treatment plan.

Nevertheless, the study adds to a growing body of evidence suggesting that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss — potentially reshaping how chronic musculoskeletal conditions are managed in the years ahead.